Citations

Clear

1794 citation(s) found for "Yu, Stephanie".

Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study
Brito, Juan P. , Payne, Stephanie , Ospina, Naykky Singh , Rodríguez‐Gutiérrez, René , Maraka, Spyridoula , Sangaralingham, Lindsey R. , Iñiguez‐Ariza, Nicole M. , Stan, Marius N. , Singh Ospina, Naykky, Maraka, Spyridoula , Stan, Marius N , Singh Ospina, Naykky , Brito, Juan P , Montori, Víctor M.

Mayo Clinic

Thyroid | January 24, 2020 | Volume: 30 | Issue: 3 | Pages: 357-364

10.1089/thy.2019.0132 | PMID 31973681 Get It

Deep inspirations attenuate postprandial airway inflammation in college-aged adults with elevated baseline exhaled nitric oxide: A pilot study
Kurti, Stephanie P. , Smith, Joshua R. , Rosenkranz, Sara K. , Emerson, Sam R. , Edwards, Elizabeth S. , Jurrens, Kayla, Laughlin, A., Kurti, S P , Edwards, E S , Smith, Joshua R , Harms, Craig A.

Mayo Clinic

Experimental Lung Research | January 16, 2020 | Volume: 46 | Issue: 1-2 | Pages: 32-43

10.1080/01902148.2020.1713923 | PMID 31941389 Get It

Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities
Folseraas, Trine , Roessler, Stéphanie , Kloor, Matthias , Endris, Volker , Buchhalter, Ivo , Stenzinger, Albrecht , Grzyb, Krzysztof , Grimsrud, Marit M. , Górnicka, Barbara , Seth, Erik von , Reynolds, Gary , Gotthardt, Daniel , Cheung, Angela , Verheij, Joanne , Arola, Johanna, Mäkisalo, Heikki, Eide, Tor J., Weidemann, Sören , Cheville, John C. , Ponsioen, Cyriel Y. , Bergquist, Annika , Manns, Michael P. , Färkkilâ, Martti , Vogel, Arndt , Group, International PSC Study, Boberg, Kirsten Muri , Schirmacher, Peter , Karlsen, Tom H. , Lazaridis, Konstantinos N. , Buchhalter, Ivo , Bergquist, Annika , Vogel, Arndt , Goeppert, Benjamin Frank , Volckmar, Anna‐Lena , Franke, André , Mehrabi, Arianeb , Mazza, Giuseppe Antonio , Hirschfield, Gideon M. , Milkiewicz, Piotr , Schramm, Christoph , Group, International PSC Study

Mayo Clinic

Hepatology | January 11, 2020 | Volume: 72 | Issue: 4 | Pages: 1253-1266

10.1002/hep.31110 | PMID 31925805 Get It

Background and Aims Lifetime risk of biliary tract cancer (BTC) in primary sclerosing cholangitis (PSC) may exceed 20%, and BTC is currently the leading cause of death in patients with PSC. To open new avenues for management, we aimed to delineate clinically relevant genomic and pathological features of a large panel of PSC‐associated BTC (PSC‐BTC). Approach and Results We analyzed formalin‐fixed, paraffin‐embedded tumor tissue from 186 patients with PSC‐BTC from 11 centers in eight countries with all anatomical locations included. We performed tumor DNA sequencing at 42 clinically relevant genetic loci to detect mutations, translocations, and copy number variations, along with histomorphological and immunohistochemical characterization. Regardless of the anatomical localization, PSC‐BTC exhibited a uniform molecular and histological characteristic similar to extrahepatic cholangiocarcinoma. We detected a high frequency of genomic alterations typical of extrahepatic cholangiocarcinoma, such as TP53 (35.5%), KRAS (28.0%), CDKN2A (14.5%), and SMAD4 (11.3%), as well as potentially druggable mutations (e.g., HER2/ERBB2). We found a high frequency of nontypical/nonductal histomorphological subtypes (55.2%) and of the usually rare BTC precursor lesion, intraductal papillary neoplasia (18.3%). Conclusions Genomic alterations in PSC‐BTC include a significant number of putative actionable therapeutic targets. Notably, PSC‐BTC shows a distinct extrahepatic morpho‐molecular phenotype, independent of the anatomical location of the tumor. These findings advance our understanding of PSC‐associated cholangiocarcinogenesis and provide strong incentives for clinical trials to test genome‐based personalized treatment strategies in PSC‐BTC.
1133: VAGUS NERVE STIMULATION FOR INTRACTABLE VOMITING CAUSES POSTOPERATIVE STRIDOR
Carmon, Stephanie, Matos, Nikki , Divertie, Gavin D.

Mayo Clinic

Critical Care Medicine | December 18, 2019 | Volume: 48 | Issue: 1 | Pages: 546-546

10.1097/01.ccm.0000643468.30438.a9 Get It

1705: ANGIOTENSIN II: ADJUNCTIVE THERAPY FOR REFRACTORY VASODILATORY SHOCK
Carmon, Stephanie, Matos, Nikki , Burnside, Rebecca, Sanghavi, Devang , Franco, Pablo Moreno

Mayo Clinic

Critical Care Medicine | December 18, 2019 | Volume: 48 | Issue: 1 | Pages: 827-827

10.1097/01.ccm.0000649120.71040.58 Get It

Knee Biomechanical Deficits During a Single-Leg Landing Task Are Addressed With Neuromuscular Training in Anterior Cruciate Ligament–Reconstructed Athletes
Nagelli, Christopher V. , Stasi, Stephanie Di , Wordeman, Samuel C., Chen, Albert , Tatarski, Rachel L. , Hoffman, Joshua, Hewett, Timothy E.

Mayo Clinic

Clinical Journal of Sport Medicine | December 16, 2019 | Volume: 31 | Issue: 6 | Pages: e347-e353

10.1097/jsm.0000000000000792 | PMID 31842056 Get It

Objective: Faulty neuromuscular and biomechanical deficits of the knee are nearly ubiquitous in athletes after anterior cruciate ligament (ACL) reconstruction (ACLR). Knee biomechanical deficits are directly associated with an increased risk of second ACL injury, which typically occurs during a sports-related movement on a single limb. To date, the biomechanical effects of a neuromuscular training (NMT) program on knee biomechanics during a single-leg landing task have not been investigated. Design: Prospective Cohort Study. Setting: Controlled laboratory setting. Participants: Eighteen ACLR and 10 control athletes. Interventions: Neuromuscular training. Main Outcome Measures: Knee kinematics and kinetics. Results: There were no significant interactions of session and limb (P > 0.05) for the athletes with ACLR after training. However, there were several significant main effects of session (P < 0.05) for knee kinematics and kinetics during the single-leg landing task. After training, the athletes with ACLR landed with greater knee flexion angles, decreased knee abduction angles, increased knee flexion range of motion, and decreased knee excursion. Also, the ACLR athletes landed with lower knee flexion moments, greater knee adduction moments, and lower peak vertical ground reaction force. Post-training comparison of the ACLR and control cohorts found no significant interactions of group and limb (P > 0.05) and only a significant main effect of group (P < 0.05) for frontal plane knee angle at initial contact. The athletes with ACLR landed with greater knee adduction angles than the control group. Conclusions: Deficits in knee biomechanics that are associated with an increased risk of ACL injury are attenuated after completion of this NMT program.
Genome-Wide Association Study Identifies an Immune-Related Etiology for Severe Aplastic Anemia
Viard, Mathias , Zhou, Weiyin , Li, Shengchao, Wang, Tao , Vogt, Aurélie , Hicks, Belynda , Burdett, Laurie, Chung, Charles C., Andrade, Kelvin de, Berndt, Sonja I. , Rothman, Nathaniel , Lan, Qing , Haagenson, Michael , Wang, Youjin , Mary, Carrington, Gadalla, Shahinaz M. , Gadalla, Shahinaz M , Savage, Sharon A. , Yeager, Meredith , Ó’hUigín, Colm , Dean, Michael , Freedman, Neal D. , Rothman, Nathaniel , Cerhan, James R. , Slager, Susan L. , Zhang, Yawei , Teras, Lauren R. , Chanock, Stephen Jacob , Spellman, Stephen R. , Willis, Amanda, Askar, Medhat , Lee, Stephanie J.

Mayo Clinic

Blood | November 14, 2019 | Volume: 134 | Issue: Supplement_1 | Pages: 1224-1224

10.1182/blood-2019-128235 Get It

Introduction. Acquired severe aplastic anemia (SAA) is a life-threatening disorder characterized by severe progressive pancytopenia and hypocellular bone marrow. The etiology of acquired SAA is not understood but believed to be related to abnormal immune responses to environmental exposures. We conducted a genome-wide association study (GWAS) to identify common germline variants associated with SAA. Methods. We identified 895 patients with SAA who underwent related or unrelated hematopoietic cell transplant (HCT) with clinical data and pre-HCT blood samples available in the Center for International Blood and Marrow Transplant Research (CIBMTR) database and biorepository. Pre-HCT DNA was extracted from blood of patients with SAA and genome-wide genotyping was conducted using the Illumina OmniExpress array. We excluded 93 inherited bone marrow failure cases. The SAA cases were grouped cases into discovery and validation sets based on time of batch sample receipt. Analyses were limited to patients of European ancestry based on principal component analyses to minimize the potential effect of population stratification. Controls were genomically matched and selected from previously scanned cancer-free subjects at the Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, NCI. The final analysis included 534 acquired SAA cases (359 in the discovery set and 175 in the validation set), and 2,455 controls (1,396 in the discovery set, and 1,059 in the validation set). Results. Patients with SAA in this study received HCT between 1989-2015 at a median age of 21 years, 56% were male, and the median time between SAA diagnosis and HCT was 11 months. Strong genome-wide association signals were identified across the human leukocyte antigen (HLA) genes encoded at the major histocompatibility complex (MHC) on chromosome 6p21 (Figure 1). The top SNP was located in the P4 binding pocket of the HLA class II gene HLA-DPB1(rs1042151A>G, p.Met105Val, pooled-odds ratio [OR]=1.75, 95% confidence interval [CI]=1.50-2.03, p=1.94x10-13). The expression of HLA-DP in CD19+ cells from 175 healthy donors was significantly different by rs1042151 A>G genotype (p=2.04x10-6) (Figure 2). A second SNP near HLA-B, rs28367832G>A, also reached genome-wide significance (pooled-OR=1.49, 95% CI=1.22-1.78, p=7.27x10-9). Copy-number variant analysis and next generation sequencing also identified somatic, clonal copy-neutral loss-of-heterozygosity affecting class I HLA genes in 8.6% of the SAA cases and none of the controls. Conclusion. This SAA GWAS identified strong association signals between common germline genetic variants in HLA class I and II genes and SAA. The main SNP is associated with changes in HLA-DP expression suggesting a key role for this locus in SAA etiology. This study adds further evidence to the connection between SAA and immune dysregulation. Disclosures Cerhan: Janssen: Membership on an entity's Board of Directors or advisory committees; NanoString: Research Funding; Celgene: Research Funding. Lee:Incyte: Research Funding; Syndax: Research Funding; Amgen: Research Funding; Novartis: Research Funding; Takeda: Research Funding; Kadmon: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; AstraZeneca: Research Funding.
What's in a Name? a Gender-Based Analysis of Speaker Introductions at the American Society of Hematology Annual Meeting
Duma, Narjust , Slostad, Jessica , Wee, Christopher Eing , Kusne, Yael , Bernabe, Carolina , Woods, Cynthia , Murphy, Martina, Knoll, Miriam A., Durani, Urshila , Patel, Shruti , Velázquez, Ana I. , Jain, Shikha , Graff, Stephanie L. , Marshall, Ariela L.

Mayo Clinic

Blood | November 14, 2019 | Volume: 134 | Issue: Supplement_1 | Pages: 3411-3411

10.1182/blood-2019-131484 Get It

Introduction: Several recent studies have shown a gender disparity in professional doctoral introductions at major medical conferences, with female speakers being less likely to be introduced with a professional title. We sought to examine whether a similar disparity existed at the American Society of Hematology (ASH) Annual Meeting. Methods: In this retrospective observational study, 8 investigators reviewed available presentations from video archives of the 2018 ASH Annual Meeting. Presentations were excluded if gender could not be identified and/or speaker did not have a doctoral degree. We collected data on speaker gender, speaker academic/non-academic rank, speaker geographic location, speaker training status, speaker session type and introducer gender were all collected. A "professional address" was defined as either "Dr. [First and Last Name]" or "Dr. [Last Name]." Descriptive statistics and regression modelling were used to analyze the data. Results:Of the videos reviewed, 645 presentations were eligible for analysis; 380 (59%) speakers were men and 264 (41%) were women. A comparison of male and female speaker cohorts is seen in Table 1. Forty-eight percent of both men and women held a Medical Doctor degree (MD), and the rest were MD/PhD or PhD graduates. Substantially more men (28%) were full professors compared to women (13%). Almost half (47%) of session types for both men and women speakers were designated as "basic science." In an adjusted analysis, more women (N=174, 66%) compared to men (N=225, 59%) received a professional address (P&lt;.01). 43% of women were introduced by a female introducer and 42% of men were introduced by a female introducer (P=.79). In addition, 48 of the introducers (19%) for women and 68 of the introducers (18%) for men had a PhD or MD/PhD. In a logistic regression model adjusting for session type, academic rank, degree, geographic location, trainee status, and gender of introducer, there were no significant gender-based differences in professional introduction [Table 1; Odds Ratio (OR) 0.71, P=.06]. In addition, speakers with MD introducers were more likely to have a professional introduction compared to PhD introducers (OR 2.15, P=.03) regardless of sex. Conclusions: Our study demonstrates that women were at least as likely as men to receive a professional address at the 2018 ASH Annual Meeting. These results differ from previous studies of other professional medical conferences. These findings may reflect the strong presence of PhD graduates as both speakers and introducers. Both forms of bias (gender and degree-based) merit further study and interventions including speaker training to ensure combatting unconscious bias. Disclosures Velazquez: Midatech: Other: Husband owns stock in this company; Portola Pharmaceuticals: Other: Husband owns stock in this company; Corbus Pharmaceuticals: Other: Husband owns stock in this company; Johnson & Johnson: Other: Husband is employed by this company.
Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
Alegria, Victoria R., LaPlant, Betsy, Sher, Taimur , Edwards, Brett , Lanier, Stephanie, Jackson, Keisha , Chanan‐Khan, Asher , Paulus, Aneel , Paulus, Aneel , Ailawadhi, Sikander , Ahmed, Salman , Manna, Alak , Parrondo, Ricardo D , Roy, Vivek , Edwards, Brett

Mayo Clinic

Blood | November 14, 2019 | Volume: 134 | Issue: Supplement_1 | Pages: 3137-3137

10.1182/blood-2019-128610 Get It

Background: The development of novel treatment strategies has extended the median survival of MM to nearly a decade but the disease remains incurable and relapse is inevitable. The Bcl-2 pathway is highly relevant to MM cell survival and can be mitigated therapeutically. AT-101 is a novel, orally available pan Bcl-2 inhibitor (Bcl-2, Bcl-xl, Mcl-1, and Bcl-w). Preclinical in vitro and in vivo studies showed that AT-101 enhanced cytotoxicity of lenalidomide-dexamethasone (Rd). We conducted a phase I study in RRMM patients to establish the effective dose of AT-101 with Ld as well as record safety and preliminary efficacy of this combination (NCT02697344). Methods: Key eligibility criteria included: RRMM with measurable disease (serum monoclonal protein ≥1.0 g/dL or urine monoclonal protein >200mg/24 hour or serum immunoglobulin free light chain >10mg/dL AND abnormal serum free light chain ratio). Patients must have received 1-3 prior treatment regimens and have an absolute neutrophil count ≥1.0 x 109, platelets 75 x 109, creatinine clearance ≥50 mL/min, and ECOG performance status ≤2. AT-101 dosing was designed to reach a maximum daily target of 20mg (Cohort 1; 10 mg PO QD, Cohort 2; 20 mg PO QD) utilizing a standard 3 +3 dose escalation design in combination with standard doses of Rd. Treatment was given as outpatient for a maximum of 12, 28-day cycles. For pharmacodynamic studies, AT-101 alone was given in cycle 1, with R (25 mg on days 1-21) and d (40 mg weekly) added cycle 2 onwards. Results: Enrolled patients (n=10) included 60% males with median age 68.5 years (range 55-75) and median time since MM diagnosis 4.5 years (range 0.6-8.3). MM ISS stage was II/III in 7 patients and 8/10 had high-risk cytogenetics with 4 each having del17p and 1q+. Only 1 patient had t(11;14).Patients had received median 2 prior lines of therapy (range 1-3), with 7 having had prior autologous stem cell transplant (ASCT) and the initial induction regimen being bortezomib (V), R and dexamethasone (d) (VRd) in 8, Rd in 1 and cyclophosphamide (C) with Vd (VCd) in 1 patient. At the time of study entry, 3 patients were R refractory while 2 were refractory to both, V and daratumumab (Dara). Median duration of treatment was 7.5 cycles (range 2-12) and 3 patients completed all planned 12 cycles of treatment. Among the evaluable patients, dose limiting toxicities (DLTs) at 20 mg daily dose of AT-101 with 25 mg of R and 40 mg weekly included one patient with grade 4 febrile neutropenia and grade 4 neutropenia lasting 9 days and one patient with grade 4 thrombocytopenia lasting 8 days. G3/4 adverse events (AEs) included atrial flutter (n=1), white blood cell count decrease (n=3), neutropenia (n=5), febrile neutropenia (n=1) and thrombocytopenia (n=2), and back pain (n=1) . No G3/4 non-hematological AEs were noted. Any grade non-hematologic AEs seen in at least 20% (n=2) patients included fatigue (n=9), neuropathy (n=6), nausea (n=3), diarrhea (n=5), constipation (n=3), and creatinine increased (n=2). No patients experienced tumor lysis syndrome. Overall response rate (ORR) was 44% (2 each with very good partial response, VGPR and PR) and clinical benefit rate (CBR) was 89% with 2 additional patients showing minor response (MR) and 2 experiencing stable disease (SD) (Fig 1). Patients with high-risk disease had an ORR of 43% and a CBR of 100%. Median progression-free survival (PFS) for all patients was 8.1 months. Correlative analysis from patients who showed an objective response to treatment revealed a significant increase in bone marrow Th-effector cells, NK cells and cytotoxic CD8+ T-cells along with a significant decrease in immunosuppressive T-regulatory and B-regulatory cells was noted after 1 complete cycle of the combination therapy (p<0.05, Fig 2). Conclusions: This is the first reported clinical trial combining a Bcl-2 inhibitor with immunomodulatory drugs (IMiDs) in MM. AT-101-Rd is a clinically active regimen with an ORR of 40% in predominantly high-risk RRMM patients with an acceptable toxicity profile. Additional patients with MM experienced clinical benefit despite refractory status to prior therapy in this early phase clinical trial. These early findings support the further investigation of AT-101 specifically, and Bcl-2 inhibitors in general, with IMiDs in patients with MM. Disclosures Ailawadhi: Celgene: Consultancy; Amgen: Consultancy, Research Funding; Pharmacyclics: Research Funding; Cellectar: Research Funding; Janssen: Consultancy, Research Funding; Takeda: Consultancy. Chanan-Khan:Xencor: Research Funding; Pharmacyclics: Research Funding; Merck: Research Funding; Jansen: Research Funding; Mayo Clinic: Employment; Ascentage: Research Funding; Millennium: Research Funding; AbbVie: Research Funding. OffLabel Disclosure: AT-101 is not currently FDA-approved for treatment of any condition.